These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22493298)

  • 21. Activation-dependent alpha5beta1 integrin-mediated adhesion to fibronectin decreases proliferation of chronic myelogenous leukemia progenitors and K562 cells.
    Lundell BI; McCarthy JB; Kovach NL; Verfaillie CM
    Blood; 1996 Mar; 87(6):2450-8. PubMed ID: 8630410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo.
    Zhao RC; McIvor RS; Griffin JD; Verfaillie CM
    Blood; 1997 Dec; 90(12):4687-98. PubMed ID: 9389683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.
    Čokić VP; Mojsilović S; Jauković A; Kraguljac-Kurtović N; Mojsilović S; Šefer D; Mitrović Ajtić O; Milošević V; Bogdanović A; Đikić D; Milenković P; Puri RK
    Blood Cells Mol Dis; 2015 Dec; 55(4):373-81. PubMed ID: 26460262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic myelogenous leukemia primitive hematopoietic progenitors demonstrate increased sensitivity to growth factor-induced proliferation and maturation.
    Bhatia R; Munthe HA; Williams AD; Zhang F; Forman SJ; Slovak ML
    Exp Hematol; 2000 Dec; 28(12):1401-12. PubMed ID: 11146162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.
    Diaz-Blanco E; Bruns I; Neumann F; Fischer JC; Graef T; Rosskopf M; Brors B; Pechtel S; Bork S; Koch A; Baer A; Rohr UP; Kobbe G; von Haeseler A; Gattermann N; Haas R; Kronenwett R
    Leukemia; 2007 Mar; 21(3):494-504. PubMed ID: 17252012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
    Gentil M; Hugues P; Desterke C; Telliam G; Sloma I; Souza LEB; Baykal S; Artus J; Griscelli F; Guerci A; Johnson-Ansah H; Foudi A; Bennaceur-Griscelli A; Turhan AG
    PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypersensitivity of bcr-abl-positive progenitors to hyperthermia in patients with chronic myeloid leukemia.
    Thijsen SF; van Oostveen JW; Schuurhuis GJ; Theijsmeijer AP; Oudejans CB; van Wijk IJ; Langenhuijsen MM; Ossenkoppele GJ
    Leukemia; 1997 Oct; 11(10):1762-8. PubMed ID: 9324298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal.
    Delforge M; Boogaerts MA; McGlave PB; Verfaillie CM
    Blood; 1999 Jan; 93(1):284-92. PubMed ID: 9864172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting FEN1 Suppresses the Proliferation of Chronic Myeloid Leukemia Cells Through Regulating Alternative End-Joining Pathways.
    Zhu Y; Dai H; Wang Y; Liang Y; Feng W; Yuan Y
    DNA Cell Biol; 2021 Aug; 40(8):1101-1111. PubMed ID: 34156283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R; Verfaillie CM
    Blood; 1998 May; 91(9):3414-22. PubMed ID: 9558400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.
    Slupianek A; Falinski R; Znojek P; Stoklosa T; Flis S; Doneddu V; Pytel D; Synowiec E; Blasiak J; Bellacosa A; Skorski T
    Leukemia; 2013 Mar; 27(3):629-34. PubMed ID: 23047475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
    Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new assay capturing chromosome fusions shows a protection trade-off at telomeres and NHEJ vulnerability to low-density ionizing radiation.
    Pobiega S; Alibert O; Marcand S
    Nucleic Acids Res; 2021 Jul; 49(12):6817-6831. PubMed ID: 34125900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold.
    Dierov J; Sanchez PV; Burke BA; Padilla-Nash H; Putt ME; Ried T; Carroll M
    Leukemia; 2009 Feb; 23(2):279-86. PubMed ID: 19020542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability.
    Giehl M; Fabarius A; Frank O; Hochhaus A; Hafner M; Hehlmann R; Seifarth W
    Leukemia; 2005 Jul; 19(7):1192-7. PubMed ID: 15858613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
    Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R
    Blood; 2009 Dec; 114(25):5191-200. PubMed ID: 19855080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
    Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ
    J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
    Holtz MS; Forman SJ; Bhatia R
    Leukemia; 2005 Jun; 19(6):1034-41. PubMed ID: 15815728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
    Jiang G; Yang F; Li M; Weissbecker K; Price S; Kim KC; La Russa VF; Safah H; Ehrlich M
    Cancer Biol Ther; 2003; 2(1):103-8. PubMed ID: 12673129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.